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Abstract
Background—Virulence factors ofHelico-
bacter pylori are associated with peptic
ulcer disease and may be also associated
with the eYcacy of treatment.
Aims—To determine the relation between
the vacA and the cagA status of H pylori,
clinical disease, and treatment outcome.
Patients—121 patients withH pylori infec-
tion and peptic ulcer disease or functional
dyspepsia were treated by quadruple anti-
biotic therapy in two groups for one and
two days, respectively.
Methods—DNA was isolated from gastric
antral biopsy specimens, taken before and
after treatment, and the vacA and cagA
status was determined by polymerase
chain reaction and reverse hybridisation.
Results—Peptic ulcer disease was signifi-
cantly associated with the vacA s1 type,
and cagA positivity, but not with the vacA
m type. Treatment eYcacy was signifi-
cantly higher in patients with peptic ulcer
disease, or infected with cagA+/vacA s1
strains.
Conclusions—The strong association be-
tween the cagA and vacA status and peptic
ulcer disease was confirmed. Cure rates
seem to be higher for patients with cagA+/
vacA s1 H pylori strains, which is consist-
ent with the higher cure rate observed
among ulcer patients compared with
functional dyspepsia patients. Therefore,
treatment studies may require stratifica-
tion for presence of ulcers as well as H
pylori genotypes.
(Gut 2000;46:321–326)
Keywords: Helicobacter pylori; virulence; treatment;
vacA; cagA
Helicobacter pylori colonises the human stom-
ach; its persistence causes gastritis and peptic
ulcers and in some individuals may lead to the
development of gastric cancer. Clinical out-
come of infection is determined by factors such
as the age of acquisition, environment, host
factors, and genetic heterogeneity of H pylori.1 2
At present, several virulence associated genes
have been identified in the genome of H pylori:
vacA, cagA, and iceA.3–6 vacA is present in all H
pylori strains and encodes a vacuolating
cytotoxin.7 There are at least four vacA signal
sequence types (s1a, s1b, s1c, and s2) and three
middle region types (m1, m2a, and m2b).8
Type s1/m1 strains express more cytotoxin
activity than type s1/m2 strains, and type s2/m2
strains produce no detectable cytotoxin
activity.8 9 Discrimination between the vacA
genotypes can be useful for classifying strains
that are associated with either functional
dyspepsia or peptic ulcer disease. cagA (the
cytotoxin associated gene) is not present in all
H pylori strains, and is considered as a marker
for the presence of a pathogenicity island of
35–40 kbp in the bacterial genome. This island
contains a number of genes, whose products
are associated with increased pathogenicity of
H pylori—for example, by induction of cytokine
production in the gastric mucosa, resulting in a
more severe gastritis. This may be the reason
why cagA positive strains are more prevalent in
patients with peptic ulcers compared with
patients with gastritis only.10–13 The presence of
cagA is also strongly associated with the
presence of the vacA s1 allele.8
H pylori infection can be eVectively cured by
antibiotics. Numerous treatment regimens
have been tested over the years. Triple and
quadruple regimens containing at least two
antibiotics are the most eVective treat-
ments.14 15 Despite the success of the current
anti-helicobacter therapies, some studies have
suggested that the eradication rate among
patients with gastritis is lower than among
patients with peptic ulcer disease,16 and the
causes of this phenomenon have been the sub-
ject of speculation. As the cagA and vacA status
of H pylori is associated with the development
of peptic ulcer disease, the aim of the present
study was to determine whether the H pylori
genotype plays a role in the eYcacy of quadru-
ple antibiotic therapy.
Materials and methods
PATIENTS AND ANTI-HELICOBACTER TREATMENT
A total of 121 H pylori positive patients
clinically diagnosed with duodenal ulcer
(n=54), gastric ulcer disease (n=14), or
functional dyspepsia (n=53) was studied. All
patients were recruited consecutively at one
gastroenterology unit and lived in the south-
eastern part of The Netherlands. The patients
took part in two studies to determine the
eYcacy of particular treatments for H pylori
infection and were combined for the purposes
of this study. Table 1 summarises the patient
characteristics.
Forty six patients (33 with peptic ulcer
disease and 13 with non-ulcer dyspepsia) were
treated in group I with lansoprazole 30 mg
twice daily on days 1–4.17 On day 4 they
received colloidal bismuth subcitrate 120 mg,
tetracycline hydrochloride 250 mg, and metro-
nidazole 250 mg at 0900, 1100, 1300, 1500,
1700, 1900, 2100, and 2300 hours.
Abbreviations used in this paper: PCR, polymerase
chain reaction.
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Seventy five patients (35 with peptic ulcer
disease and 40 with non-ulcer dyspepsia) were
treated in group II with lansoprazole 30 mg
twice daily on days 1–5. On days 4 and 5 they
also received colloidal bismuth subcitrate 120
mg four times daily, tetracycline 500 mg four
times daily, and metronidazole 500 mg four
times daily.18 Four patients were not available
for follow up.
All patients were completely compliant, as
determined by administration of medication in
the hospital during the one day treatment
(group I), pill counts, and patient interviews.
Antral biopsy specimens were placed in 1 ml
of thioglycollate broth and transported to the
microbiology laboratory within six hours of
endoscopy. One biopsy specimen was kept fro-
zen at −70°C and later used for polymerase
chain reaction (PCR), and the other was
immediately used for culture. Before treat-
ment, all patients were H pylori positive in
endoscopic biopsy specimens from antrum and
corpus, as determined by the CLO test, histol-
ogy (Giemsa stain), and culture.
CULTURE OF H PYLORI
Bacteria were cultured on Belo-Horizonte
medium containing brain-heart infusion agar
(35 g/l), sheep’s blood (10%), vancomycin (10
mg/l), trimethoprim lactate (5 mg/l), cefsolu-
dine (5 mg/l), and amphotericin (5 mg/l). The
plates were incubated in microaerobic condi-
tions at 37°C for seven days. Putative H pylori
colonies were confirmed by Gram staining, and
tested for catalase, oxidase, and urea hydroly-
sis.
Metronidazole and clarithromycin suscepti-
bilities were tested by the E test (AB Biodisk,
Solna, Sweden) on plates using Belo-Horizonte
medium with sheep’s blood (10%). Strains
were considered susceptible to metronidazole
when the minimal inhibitory concentration was
less than 8 µg/ml.
ANALYSIS OF vacA AND cagA
For PCR analysis, antral biopsy specimens
were used that had been taken immediately
before and six weeks after treatment and stored
in thioglycollate broth at −70°C. Specimens
were homogenised with a sterile micropestle
and DNA was isolated by the method of Boom
et al.19 The vacA and cagA status was
determined by multiplex PCR followed by
reverse hybridisation on a line probe assay
(LiPA), as described previously.20 21
STATISTICAL ANALYSIS
Data were analysed with SPSS (SPSS Inc.,
Chicago, Illinois, USA) version 8.0. Associa-
tions between categorical variables were tested
for statistical significance using ÷2 tests with
one degree of freedom; t tests were used for
normally distributed data. Logistic regression
was performed to analyse the relation between
peptic ulcer disease (combining gastric and
duodenal ulcers) and the various combinations
of cagA and vacA genotypes, and the relation
between the success of eradication therapy and
the H pylori genotypes. In both analyses the
relation with the genotypes was adjusted for
age (using categories <40, 41–50, 51–60,
61–70, and >70 years) and sex. Additional
confounders included in the second analysis
were the presence or absence of peptic ulcers,
the therapy received (group I and II), and the
sensitivity to metronidazole. Covariates (the H
pylori genotypes) were included by forward
selection on the basis of a likelihood ratio test.
A value of p<0.05 was used as a significance
level for inclusion, and odds ratios (OR) as well
as their 95% confidence intervals (CI) of
significant covariates were determined.
Results
EVALUATION OF THE EFFICACY OF TREATMENT BY
PCR
A total of 121 patients was treated as part of a
clinical trial with either one or two day quadru-
ple therapy (table 1).17 Group I comprised 46
patients, treated for one day, and all were avail-
able for follow up analysis six weeks after
therapy by CLO test, culture, and histology,
resulting in a cure rate of 57% (26/46). Follow
up samples from two patients were not
available for PCR analysis. Based on PCR
analysis the eradication results were confirmed,
except for two cases, where results of the initial
tests were inconclusive, and according to the
protocol they were initially considered as not
cured. In one of these cases, histology and cul-
ture were both negative in post-treatment
biopsy specimens from antrum and corpus.
The CLO test on the corpus specimen was
negative but positive on the antrum specimen.
PCR on the antral specimen was also positive
and this case was still considered as not cured.
In the second case only the corpus specimen
was positive in the CLO test. Giemsa staining
and culture on both antrum and corpus biopsy
specimens, CLO test, culture, and PCR tests
on the antral biopsy specimen were all negative.
The CLO test result was considered as false
positive and therefore this patient was now
considered to be cured. Overall, the final cure
rate, taking the PCR results into account, was
59% (27/46). EYcacy of treatment was higher
in patients with peptic ulcer disease (22/33;
67%) compared with those with functional
dyspepsia (5/13; 39%; ÷2=3.06; p=0.08).
In the second group, a total of 75 patients
was treated for two days, but follow up was not
available in four patients. The initial cure rate
was 72% (51/71) based on negative results of
Table 1 Characteristics of patients in groups I and II
Group I (n=46) Group II (n=75)
Significance
(group I v group II)
PUD (%) 33 (72) 35 (47) ÷2=7.281; p<0.01
NUD (%) 13 (28) 40 (53)
Men (%) 31 (67) 49 (65) ÷2=0.054; p=0.816
Age (SD (range)) 15.7 (23–85) 13.6 (23–82) p=0.830
Initial cure rate* (%) 26/46 (57) 51/71‡ (72) ÷2=2.908; p=0.08
Final cure rate† (%) 27/46 (59) 46/71 (65) ÷2=0.442; p=0.506
Final cure rate PUD (%) 22/33 (67)§ 26/34 (76)§ ÷2=0.792; p=0.373
Final cure rate NUD (%) 5/13 (39) 20/37 (54) ÷2=0.936; p=0.330
*Based on CLO test, culture, and histopathology results of the post-treatment biopsy specimens.
†Taking PCR on post-treatment biopsy specimens into account.
‡Follow up samples from four cases were not available.
§DiVerence between final cure rate of patients with peptic ulcer disease (PUD) compared with
patients with non-ulcer dyspepsia (NUD) was not significant in group I (÷2=3.06; p=0.08), but
was in group II (÷2=3.903; p=0.04).
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the CLO test, histology, and culture on gastric
biopsy specimens taken six weeks after therapy.
Post-treatment biopsy specimens from these 71
cases were also available for PCR analysis.
Among the post-treatment biopsy specimens
that were scored negative by CLO, culture, and
histology, positive PCR results were obtained
in five cases, and these were therefore consid-
ered as not cured. Thus, the final cure rate,
taking PCR results into account, was 65% (46/
71) among patients available for evaluation. As
in group I, eYcacy of treatment in this group
was also higher among patients with peptic
ulcer disease (26/34; 76%) compared with
those with functional dyspepsia (20/37; 54%;
÷2=6.85; p<0.01).
ANALYSIS OF THE PRETREATMENT BIOPSY
SPECIMENS
To assess the relation between clinical symp-
toms and H pylori genotypes, pretreatment
biopsy specimens were analysed. Table 2 shows
the cagA status as well as the vacA genotypes
determined in pretreatment biopsy specimens.
vacA s1/m1, s1/m2, s2/m2, and multiple geno-
types were found in 38 (31.4%), 46 (38.0%),
24 (19.8%), and 13 (10.7%) of the 121 cases,
respectively. Of the 84 strains containing vacA
type s1, 73 (86.9%) were subtype s1a and 11
(13.1%) were s1b.
To investigate the relation between geno-
types and peptic ulcer disease, the 13 cases
with multiple genotypes were excluded from
statistical analysis. Thus, 108 patients with a
single vacA/cagA genotype in the pretreatment
biopsy specimen were used for further statisti-
cal analyses. Univariate analyses (using the ÷2
test) of the H pylori genotypes yielded the
following results. cagA was present in 67
(62.0%) of the 108 strains, and its presence
was significantly associated with the presence
of vacA type s1 (÷2=44.231; p<0.001; group I:
p=0.005; group II: p<0.001) and type m1
(÷2=12.114; p=0.001; group I: p=0.236; group
II: p=0.001). All s2/m2 cases were cagA nega-
tive. Peptic ulcer disease was strongly associ-
ated with the presence of cagA (÷2=6.641;
p=0.002; group I: p=0.017; group II: p=0.012)
and vacA s1 (÷2=9.765; p=0.001; group I:
p=0.004; group II: p=0.035), but not with the
vacA m type (÷2=0.074; p=0.444, group I:
p=0.664; group II: p=0.418). These results are
in agreement with earlier findings.6 9
Logistic regression analysis relating ulcer
disease to H pylori genotypes confirmed that
the presence of ulcers is not significantly
related to the vacA m region. Through forward
selection, cagA was selected as the only signifi-
cant predictor variable (OR cagA+ versus
cagA− = 8.1, CI: 2.9 to 22.6). However, owing
to the very close association between cagA
positivity and presence of the vacA s1 geno-
type, an approximately equal fit (with similar
likelihoods) was obtained when including the
vacA s genotype instead of the cagA genotype
(OR s1 versus s2 = 9.9, CI: 2.9 to 33.7).
RELEVANCE OF H PYLORI GENOTYPE FOR THE
EFFICACY OF ANTIBIOTIC THERAPY
To study the relation between the vacA and
cagA genotypes and treatment eYcacy, pre-
treatment and post-treatment biopsy speci-
mens were analysed from both patient groups.
Taken together, among the 121 patients, six
cases with a single genotype before treatment
showed a diVerent vacA/cagA genotype during
follow up, of which four were multiple and two
single genotypes (table 3). Furthermore, post-
treatment biopsy specimens were not available
for genotyping in six cases. Among the 109
treated patients available for analysis, therapy
was eVective in 72 patients, but failed in 37
cases. Table 4 shows the association between
treatment outcome and the cagA and vacA
genotypes. Again, the cases containing multiple
genotypes (12 of the 109 cases) were excluded.
Univariate analyses (using the ÷2 test) showed
the following relations. Therapy was signifi-
cantly more eVective in ulcer patients com-
pared with non-ulcer patients (÷2=6.356;
p=0.012; group I: p=0.108; group II:
p=0.024). cagA+ strains seemed to be more
easily eradicated than cagA− strains
(÷2=10.638; p=0.001; group I: p=0.036; group
II: p=0.015). Similarly, therapy was more
eVective for vacA s1 strains than for s2 strains
(÷2=4.845; p=0.028; group I: p=0.025; group
II: p=0.247), but there was no significant
Table 2 Relation between Helicobacter pylori cagA and vacA genotypes in pretreatment biopsy specimens and clinical
diagnosis
vacA
genotype
Duodenal ulcer (n=54) Gastric ulcer (n=14) Functional dyspepsia (n=53)
TotalcagA+ cagA− cagA+ cagA− cagA+ cagA−
Group 1
s1/m1 7 1 2 – 1 2 13 (28.3%)
s1/m2 9 4 2 2 2 1 20 (43.3%)
s2/m2 – 1 – 1 – 5 7 (15.2%)
Multiple 4 – – – 1 1 6 (13.0%)
Group II
s1/m1 9 – 3 1 11 1 25 (33.3%)
s1/m2 11 1 2 – 8 4 26 (34.6%)
s2/m2 – 3 – 1 – 13 17 (22.7%)
Multiple 4 – 1 7 (9.3%)
Total 44 10 9 5 25 28 121
Table 3 Helicobacter pylori vacA and cagA status of cases
with non-matching pretreatment and post-treatment
genotypes
Patient
Genotype in pretreatment
biopsy
Genotype in post-treatment
biopsy
1 s1a/m1/cagA+ s2/m2/cagA−
2 s1a/m2/cagA+ s1a/m1/m2/cagA+
3 s1a/m1/cagA+ s1a/s2/m1/m2/cagA+
4 s1a/m2/cagA+ s1a/s2/m2/cagA+
5 s1a/m1/cagA+ s1a/m2/cagA+
6 s1a/m2/cagA− s1a/m1/m2/cagA+
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relation with the vacA m region type
(÷2=1.046; p=0.306; group I: p=0.690; group
II: p=0.371).
Among the 109 strains cultured from
pretreatment biopsy specimens, 75 strains
(68.8%) were sensitive to metronidazole, and
14 (12.8%) were resistant. The cure rate was
lower in patients infected with metronidazole
resistant strains compared with patients in-
fected by metronidazole sensitive cases, but
this diVerence did not reach statistical signifi-
cance (÷2=3.018; p=0.08). All strains were
sensitive to clarithromycin. The antibiotic sus-
ceptibility of 20 (18.3%) strains could not be
determined.
Logistic regression analysis was used to
assess the relation between outcome of therapy
with the H pylori genotypes. If adjusted for the
potential confounders age, sex, presence of
ulcer disease, and therapy received, the only
significant covariate was the vacA s genotype
(OR s1 versus s2 = 3.6, CI: 1.02 to 12.3). In
contrast to the relation between peptic ulcer
disease and genotypes, none of the other geno-
types was selected when the vacA s genotype
was excluded from the analysis. It could, how-
ever, be argued that ulcer disease should not be
included as a confounder as presence of peptic
ulcer disease itself is highly dependent on the H
pylori genotypes, as shown in the first part of
the study. When excluding ulcer disease as a
confounder, the association with the vacA s
genotype (again the only significant covariate)
was much more pronounced (OR s1 versus s2
= 4.6, CI: 1.4 to 15.0). Furthermore, when
vacA s genotype was excluded from the analy-
sis, cagA was selected as a significant covariate
(OR cagA+ versus cagA− = 3.0, CI: 1.17 to
7.9), which is consistent with the strong associ-
ation between cagA+ and the vacA s1 geno-
types.
Multiple vacA genotypes were detected in 12
of 109 patients (11.0%) with a complete follow
up and matching pretreatment and post-
treatment biopsy specimens (table 5). Therapy
failed in six of these patients, and in four, only
single genotypes were detected in the post-
treatment biopsy specimen; in the remaining
two patients, the same combination of vacA
genotypes was also detected after treatment.
From one patient (table 5, patient 4) with a
mixed s1a/s2/m1/m2/cagA+ genotype before
therapy, a metronidazole resistant strain was
cultured. After treatment, only a s1a/m2/cagA−
genotype was identified in the biopsy speci-
men, and the cultured strain was metronida-
zole sensitive.
Discussion
In order to eradicate H pylori from the human
stomach, triple and quadruple therapies with
bismuth salts, multiple antibiotics, H2 antago-
nists, and proton pump inhibitors for 4–14
days can reach per protocol cure rates of more
than 90%. As compliance is an important fac-
tor for treatment failure, shorter therapies have
been investigated. Earlier studies have indi-
cated diVerent cure rates between ulcer and
non-ulcer patients.16 22 Furthermore, the as-
sociation between peptic ulcer disease and sev-
eral virulence genes of H pylori has been
described.4 6 The aim of the present study was
to address the relation between peptic ulcer
disease, the eYcacy of H pylori eradication, and
the status of the virulence associated vacA and
cagA genes.
Genotyping of H pylori was performed
directly on gastric biopsy specimens, which
provides information on the actual infection in
the stomach. Diagnostic findings of histology,
culture, and CLO test were confirmed by PCR
in all but six cases, where follow up biopsy
specimens were positive by PCR only. This
may reflect the extremely high sensitivity of
PCR compared with other diagnostic
methods.23 Although PCR detection does not
discriminate between live and dead bacteria,
the detection of H pylori DNA at six weeks after
therapy was considered as indicative of failure
to eradicate the bacterium.
The great majority of vacA s1 strains were
classified as subtype s1a. This finding is
consistent with earlier studies on the worldwide
distribution of vacA subtypes, which showed
that s1a is the predominant subtype in
northern and eastern Europe, whereas in
Table 4 Relation between presence or absence of peptic ulcer disease, cagA and vacA genotypes in pretreatment biopsy
specimens, and eYcacy of one to two days of intensified quadruple eradication treatment
Clinical status No of cases
Successful
eradication cagA status
Successful
eradication vacA status
Successful
eradication
Peptic ulcer disease 54 79.6% (43/54) pos: 39 87.2% (34/39) s1: 39 86.1% (34/39)
s2: 0 –
neg: 15 60% (9/15) s1: 9 44.4% (4/9)
s2: 6 83.3% (5/6)
Non-ulcer
dyspepsia
43 55.8% (24/43) pos: 20 70% (14/20) s1: 20 70% (14/20)
s2: 0 –
neg: 23 43.5% (10/23) s1: 7 57.1% (4/7)
s2: 16 37.5% (6/16)
Patients with multiple genotypes (n=12), incomplete follow up (n=6), and non-matching pretreatment and post-treatment
genotypes (n=6) were excluded from this table.
Table 5 Pretreatment and post-treatment vacA and cagA status of cases containing
multiple genotypes in the pretreatment biopsy specimen
Patient
Genotype in
pretreatment biopsy Treatment outcome
Genotype in
post-treatment biopsy
1 s1a/m1/m2/cagA+ Cured –
2 s1a/s2/m1/m2/cagA+ Cured –
3 s1a/s2/m1/m2/cagA+ Not cured s1a/s2/m1/m2/cagA+
4 s1a/s2/m1/m2/cagA+ Not cured s1a/m2/cagA−
5 s1b/s2/m1/m2/cagA+ Not cured s1b/m1/cagA+
6 s1/m1/m2/cagA− Not cured s2/m2/cagA−
7 s1a/s1b/m2/cagA+ Cured –
8 s1a/m1/m2/cagA+ Cured –
9 s1a/s2/m2/cagA− Not cured s1a/s2/m2/cagA−
10 s2/m1/m2/cagA+ Cured –
11 s1a/s2/m1/m2/cagA+ Cured –
12 s1a/s2/m1/m2/cagA+ Not cured s2/m2/cagA−
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southern Europe s1b is highly prevalent.24 The
prevalence of cagA among patients with
functional dyspepsia is lower than among
patients with peptic ulcers, and the presence of
cagA is strongly associated with the vacA s1
genotype.6 8 20 The vacA s1 allele is often
present in peptic ulcer patients, whereas geno-
type s2/m2 is more prevalent in patients
without ulcers, and there was no diVerence
between patients with gastric ulcers or duode-
nal ulcers. These results are in accord with ear-
lier reports.6 25
Genotypes were determined in pretreatment
and post-treatment biopsy specimens. Our
results indicate a diVerence in sensitivity to
therapy between the H pylori genotypes. Some
H pylori strains could be intrinsically more
prone to antibiotic treatment than others. The
present study indicated that the non toxin-
producing s2/m2 strains (which are mostly
cagA−) seem to be more resistant to therapy
than the toxin producing s1/m1 and s1/m2
strains (which are mostly cagA+). cagA+/s1
strains may proliferate faster than cagA−/s2
strains, and would be therefore more suscepti-
ble to antibiotic activity that interferes with the
metabolism of a dividing cell. Alternatively, the
more virulent genotypes may result in a diVer-
ent physiological environment in the stomach,
such as the degree of damage to the gastric epi-
thelium and mucous layer where H pylori is
residing. It is conceivable that antibiotics can
reach higher concentrations in inflamed mu-
cosa. Thus, cagA−/s2 strains, that produce less
severe inflammation, would be less accessible
to antibiotics and therefore more diYcult to
eradicate.
Patients with peptic ulcer disease seem to
reach a higher cure rate compared with patients
with functional dyspepsia.16 22 26 This was first
observed in studies using omeprazole dual
therapy and has been less apparent with the
more eVective triple and quadruple therapies,
probably owing to the small sample size of
most studies.16 22 27–31 The present study shows
that the presence of peptic ulcer disease, the
eYcacy of antibiotic therapy, and the cagA and
vacA genotypes of the H pylori strains are
strongly interrelated.
Compliance was 100% in these patients
groups, as patients of group I were treated in
the hospital, and patients from group II were
closely monitored over the short treatment
period. Therefore, lack of compliance among
patients is an unlikely explanation for the
diVerent treatment outcome.
Current therapy regimens may be particu-
larly suited to eradicate the more virulent
(s1/cagA+) H pylori strains. Future studies
should determine the genotypes of strains from
patients that did not respond to other therapy
regimens.
In six cases in which therapy was not
successful, genotyping results did not match,
and in four cases, the post-treatment biopsy
contained multiple genotypes (table 3). Rein-
fection during the follow up period is extremely
unlikely.32 Although only a single genotype was
detected before treatment, other genotypes
may already have been present before treat-
ment at a low concentration or may have
remained undetected owing to sampling varia-
tion during endoscopy. Treatment may have
shifted the absolute numbers and relative
prevalence of the diVerent genotypes. The fact
that vacA s2 genotypes were detected in three
of the six post-treatment biopsy specimens
(table 4) but not in any of the pretreatment
biopsy specimens would also be consistent with
the finding that s2 strains are more resistant to
therapy than s1 strains.
Twelve patients with a complete follow up
had multiple genotypes before treatment.
Therapy failed in six cases, and in three of
these, only a single genotype was found after
treatment. Based on the other biopsy tests,
therapy seemed to have completely failed in
these patients. However, PCR analysis indi-
cated partial eradication. From one of these
three patients, containing multiple genotypes
in the pretreatment biopsy, a metronidazole
resistant strain was cultured. After treatment
only a metronidazole sensitive strain was
cultured and a single genotype was detected.
This indicates that, although antibiotic resist-
ance is an important feature of H pylori, it is not
the crucial factor to determine the eYcacy of
treatment.
The cagA−/s2 strains can be killed with the
same antibiotics as the cagA+/s1 strains, but it
takes longer for cagA−/s2 strains. It is therefore
consistent that the diVerence in cure rate only
becomes apparent in studies which use short
treatment regimens. During prolonged treat-
ment, the more resistant cagA−/s2 strains are
also adequately killed. Hermida et al showed
that after six days of treatment more ulcer
patients were cured compared with non-ulcer
patients, but this diVerence disappeared after
prolonged (12 day) treatment.30 This finding
has important clinical implications. Treatment
studies comprising both ulcer and non-ulcer
patients may be biased. Most studies to date
were performed in ulcer patients and the high
cure rates reported may not be equally high in
a population of non-ulcer patients. Treatment
failures will also lead to an increase in the
prevalence of antibiotic resistance. Resistance
to metronidazole may be of importance for
eYcacy of treatment, but was not found to be a
dominant factor. Non-ulcer patients carrying
cagA−/s2 strains that are also metronidazole
resistant, and who stop treatment prematurely
might be expected to be the most diYcult to
cure. Therefore, diVerences in cure rates
between ulcer and non-ulcer patients are clini-
cally most relevant in areas with a high
antibiotic resistance rate.
In conclusion, diVerent genotypes of H pylori
may result in diVerent clinical outcomes and
respond diVerently to antibiotic therapy. These
findings suggest that treatment studies should
be stratified with respect to the presence of
peptic ulcers, as well as diVerent H pylori vacA
or cagA genotypes.
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